Findings hint at potentially easier treatment initiation vs. other S1P receptor modulators
Phase 3 EXPAND trial suggests potential utility of siponimod
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy